WALTHAM, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Oscient
Pharmaceuticals Corporation (Nasdaq: OSCI) will release financial results
for the fourth quarter and fiscal year ended December 31, 2007 on
Wednesday, February 6, 2008 prior to the opening of the U.S. financial
markets. A conference call will be held at 8:30 a.m. Eastern Time with
Steven Rauscher, President and CEO, and other members of Oscient's
management team. The Company announced preliminary revenue results of
approximately $80 million for fiscal year 2007 on January 14, 2008.
What: Fourth Quarter and Fiscal Year 2007 Financial Results
When: February 6, 2008 at 8:30 am Eastern Time
How: Domestic participants can access the call by dialing
International participants are asked to dial 1-706-634-5451. The call
will also be webcast through the Company's website at
Contact: Christopher Taylor, 781-398-2466 or Sarah Emond, 781-398-2544
A replay will be available two hours after the conclusion of the call until February 13, 2008. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 33514080. A replay will also be available through http://www.oscient.com.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States; ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a nationwide sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists. The Company also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium difficile-associated disease (CDAD).
For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at http://www.antararx.com and http://www.factive.com. For a complete description of the risks associated with our business please refer to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2007 and in other filings that we may make with the Securities and Exchange Commission from time to time.
|SOURCE Oscient Pharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved